Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005
Y Ji, C Rankin, S Grunberg, AE Sherrod… - Journal of Clinical …, 2015 - ascopubs.org
Y Ji, C Rankin, S Grunberg, AE Sherrod, J Ahmadi, JJ Townsend, LG Feun, RK Fredericks…
Journal of Clinical Oncology, 2015•ascopubs.orgPurpose Progesterone receptors are expressed in approximately 70% of meningiomas.
Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II
study. This multicenter, prospective, randomized, placebo-controlled phase III trial
conducted by SWOG was planned to define the role of mifepristone in the treatment of
unresectable meningioma. Patients and Methods Eligible patients were randomly assigned
to receive either mifepristone or placebo for 2 years unless disease progressed. Patients …
Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II
study. This multicenter, prospective, randomized, placebo-controlled phase III trial
conducted by SWOG was planned to define the role of mifepristone in the treatment of
unresectable meningioma. Patients and Methods Eligible patients were randomly assigned
to receive either mifepristone or placebo for 2 years unless disease progressed. Patients …
Purpose
Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma.
Patients and Methods
Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed. Patients who were stable or responding to protocol therapy after 2 years had the option to continue with the same blinded therapy. Serial follow-up allowed assessment of efficacy and toxicity. Time to treatment failure and overall survival were ascertained for all randomly assigned patients. On progression, patients receiving placebo could cross over and receive active drug.
Results
Among 164 eligible patients, 80 were randomly assigned to mifepristone and 84 to placebo. Twenty-four patients (30%) were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. Twenty-eight patients (33%) in the placebo arm completed the 2-year study. There was no statistical difference between the arms in terms of failure-free or overall survival.
Conclusion
Long-term administration of mifepristone was well tolerated but had no impact on patients with unresectable meningioma.
ASCO Publications以上显示的是最相近的搜索结果。 查看全部搜索结果